|Assessment Status||Rapid Review Complete|
|Indication||For the treatment of disease-related splenomegaly or symptoms in adults with primary myelofibrosis, post-polycythaemia vera myelofibrosis or post-essential thrombocythaemia myelofibrosis who are JAK inhibitor–naive or have been treated with ruxolitinib.|
|Rapid review commissioned||20/12/2021|
|Rapid review completed||20/01/2022|
|Rapid review outcome||A full HTA is not recommended. The NCPE recommends that fedratinib not be considered for reimbursement at the submitted price*.|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
The HSE has approved reimbursement following confidential price negotiations, December 2022.